The biotech entrepreneur who earned the nickname "Pharma Bro" after buying the rights to an existing drug and jacking up the price, has co-authored a paper from prison that examines the efficacy of existing drugs against the virus.
In an author statement at the end of the research, Shkreli asked for a three month-furlough to assist with COVID-19 research, citing his credentials as a drug industry entrepreneur.
"Medicinal chemists, structural biologists, enzymologists, and assay development and research biology departments at every pharmaceutical company should be put to work until COVID-19 is no more," Shkreli wrote.
"Being released to the post-COVID world is no solace to even the incarcerated. As a successful two-time biopharma entrepreneur, having purchased multiple companies, invented multiple new drug candidates, filed numerous [Investigational New Drug] and clinical trial applications, I am one of the few executives experienced in all aspects of drug development..."
He notes that he doesn't expect to profit from any prospective coronavirus-related treatments.
Shkreli became the face of Wall Street and drug industry greed in 2015 when his company, Turing Pharmaceuticals, raised the price of a relatively low priced AIDS drug called Daraprim by more than 5,000%.
He is currentlyfor securities fraud. The Federal Trade Commission Shkreli in January with trying to restrict competition to maintain a monopoly on a life-saving drug.